SG193141A1 - Pharmaceutical compositions with resistance to soluble cea - Google Patents

Pharmaceutical compositions with resistance to soluble cea Download PDF

Info

Publication number
SG193141A1
SG193141A1 SG2013054853A SG2013054853A SG193141A1 SG 193141 A1 SG193141 A1 SG 193141A1 SG 2013054853 A SG2013054853 A SG 2013054853A SG 2013054853 A SG2013054853 A SG 2013054853A SG 193141 A1 SG193141 A1 SG 193141A1
Authority
SG
Singapore
Prior art keywords
ser
gly
seq
thr
cea
Prior art date
Application number
SG2013054853A
Other languages
English (en)
Inventor
Ralf Lutterbuese
Petra Mayer
Evelyne Schaller
Doris Rau
Susanne Mangold
Peter Kufer
Alexander Murr
Monika Wissinger
Tobias Raum
Original Assignee
Amgen Res Munich Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Res Munich Gmbh filed Critical Amgen Res Munich Gmbh
Publication of SG193141A1 publication Critical patent/SG193141A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/14—Drugs for genital or sexual disorders; Contraceptives for lactation disorders, e.g. galactorrhoea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3007—Carcino-embryonic Antigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Pulmonology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Cephalosporin Compounds (AREA)
SG2013054853A 2005-12-21 2006-12-21 Pharmaceutical compositions with resistance to soluble cea SG193141A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US75196305P 2005-12-21 2005-12-21
EP05028064 2005-12-21
US78086106P 2006-03-10 2006-03-10

Publications (1)

Publication Number Publication Date
SG193141A1 true SG193141A1 (en) 2013-09-30

Family

ID=40413962

Family Applications (1)

Application Number Title Priority Date Filing Date
SG2013054853A SG193141A1 (en) 2005-12-21 2006-12-21 Pharmaceutical compositions with resistance to soluble cea

Country Status (24)

Country Link
US (3) US8394926B2 (enExample)
EP (2) EP1976880B1 (enExample)
JP (2) JP5399712B2 (enExample)
KR (1) KR101287777B1 (enExample)
CN (1) CN101370827B (enExample)
AU (1) AU2006328886C1 (enExample)
BR (1) BRPI0620632A2 (enExample)
CA (1) CA2633766C (enExample)
CY (1) CY1118053T1 (enExample)
DK (1) DK1976880T3 (enExample)
ES (1) ES2595091T3 (enExample)
HR (1) HRP20161216T1 (enExample)
HU (1) HUE031151T2 (enExample)
IL (1) IL192277A (enExample)
LT (1) LT1976880T (enExample)
ME (1) ME02581B (enExample)
NZ (1) NZ569204A (enExample)
PL (1) PL1976880T3 (enExample)
PT (1) PT1976880T (enExample)
RS (1) RS55181B1 (enExample)
RU (2) RU2426743C2 (enExample)
SG (1) SG193141A1 (enExample)
WO (1) WO2007071426A1 (enExample)
ZA (1) ZA200805400B (enExample)

Families Citing this family (76)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9453251B2 (en) 2002-10-08 2016-09-27 Pfenex Inc. Expression of mammalian proteins in Pseudomonas fluorescens
DE10254601A1 (de) 2002-11-22 2004-06-03 Ganymed Pharmaceuticals Ag Differentiell in Tumoren exprimierte Genprodukte und deren Verwendung
CN101031655A (zh) 2004-07-26 2007-09-05 陶氏环球技术公司 通过株工程改进蛋白表达的方法
NZ569204A (en) 2005-12-21 2012-03-30 Micromet Ag Pharmaceutical compositions with resistance to soluble CEA - comprising antibodies that bind to CD3 and CEA
WO2007071422A2 (en) * 2005-12-21 2007-06-28 Micromet Ag Pharmaceutical antibody compositions with resistance to soluble cea
US9580719B2 (en) 2007-04-27 2017-02-28 Pfenex, Inc. Method for rapidly screening microbial hosts to identify certain strains with improved yield and/or quality in the expression of heterologous proteins
US9394571B2 (en) 2007-04-27 2016-07-19 Pfenex Inc. Method for rapidly screening microbial hosts to identify certain strains with improved yield and/or quality in the expression of heterologous proteins
EP2225275A4 (en) * 2007-11-28 2013-04-03 Medimmune Llc PROTEIN FORMULATION
GB0908613D0 (en) 2009-05-20 2009-06-24 Immunocore Ltd T Cell Reseptors
WO2011034660A1 (en) 2009-09-16 2011-03-24 Immunomedics, Inc. Class i anti-cea antibodies and uses thereof
CA2782330A1 (en) * 2009-12-01 2011-06-09 Medimmune, Llc Improved methods and compositions for detecting and treating cea-expressing cancers
EP3252076B1 (en) 2011-01-14 2019-09-04 The Regents Of The University Of California Diagnostic use of antibodies against ror-1 protein
US20140242081A1 (en) * 2011-07-18 2014-08-28 Micromet Ag Dosing regimens for treatment of cea-expressing cancers
WO2013054320A1 (en) * 2011-10-11 2013-04-18 Tel Hashomer Medical Research Infrastructure And Services Ltd. Antibodies to carcinoembryonic antigen-related cell adhesion molecule (ceacam)
WO2013162748A1 (en) * 2012-04-27 2013-10-31 The Trustees Of The University Of Pennsylvania Anti-tumor endothelial marker-1 (tem1) antibody variants and uses thereof
WO2013174404A1 (en) 2012-05-23 2013-11-28 Ganymed Pharmaceuticals Ag Combination therapy involving antibodies against claudin 18.2 for treatment of cancer
AU2013302696B9 (en) 2012-08-14 2018-08-09 Ibc Pharmaceuticals, Inc. T-cell redirecting bispecific antibodies for treatment of disease
US20150231241A1 (en) 2012-08-14 2015-08-20 Ibc Pharmaceuticals, Inc. Combination therapy for inducing immune response to disease
US9682143B2 (en) * 2012-08-14 2017-06-20 Ibc Pharmaceuticals, Inc. Combination therapy for inducing immune response to disease
IL282953B2 (en) 2012-11-13 2026-02-01 Tron Translationale Onkologie An Der Johannes Gutenberg Univ Mainz Gemeinnutzige Gmbh Agents for the treatment of claudin-expressing cancers
PT3199552T (pt) 2012-11-20 2020-03-25 Sanofi Sa Anticorpos anti-ceacam5 e suas utilizações
CN110437337B (zh) 2013-02-26 2024-07-30 罗切格利卡特公司 双特异性t细胞活化性抗原结合分子
WO2014131694A1 (en) 2013-02-26 2014-09-04 Roche Glycart Ag Bispecific t cell activating antigen binding molecules
UY35484A (es) 2013-03-15 2014-10-31 Amgen Res Munich Gmbh Molécula de unión de cadena simple que comprenden ABP de extremo N
EP2930188A1 (en) * 2014-04-13 2015-10-14 Affimed Therapeutics AG Trifunctional antigen-binding molecule
JP6805428B2 (ja) 2014-04-27 2021-01-06 フェイムウェイヴ リミテッド Ｃｅａｃａｍ１に対するヒト化抗体
US11427647B2 (en) 2014-04-27 2022-08-30 Famewave Ltd. Polynucleotides encoding humanized antibodies against CEACAM1
MX2016017393A (es) 2014-07-01 2017-09-05 Pfizer Diacuerpos heterodimericos biespecificos y sus usos.
SG11201705988UA (en) 2015-02-24 2017-08-30 Bioatla Llc Conditionally active biological proteins
CN106432502B (zh) * 2015-08-10 2020-10-27 中山大学 用于治疗cea阳性表达肿瘤的双特异纳米抗体
AR106188A1 (es) 2015-10-01 2017-12-20 Hoffmann La Roche Anticuerpos anti-cd19 humano humanizados y métodos de utilización
JP7044700B2 (ja) 2015-10-02 2022-03-30 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト 二重特異性抗ｃｅａｘｃｄ３ ｔ細胞活性化抗原結合分子
IL313608A (en) 2015-12-09 2024-08-01 Hoffmann La Roche Antibody against CD20 type II to reduce the formation of antibodies against drugs
BR112018011029A2 (pt) * 2016-01-08 2018-11-21 Hoffmann La Roche métodos para tratar ou atrasar a progressão do câncer e para melhorar a função imune em um indivíduo com câncer, usos de um antagonista de ligação e de um anticorpo biespecífico, composições e kits
JP7599819B2 (ja) 2016-06-02 2024-12-16 イムノコア リミテッド ｇｐ１００特異的ＴＣＲ－抗ＣＤ３ ｓｃＦｖ融合タンパク質の投薬レジメン
CN107663240B (zh) * 2016-07-29 2021-01-12 中国人民解放军第四军医大学 高度糖基化cea特异性结合的单链抗体及其在检测和治疗上的应用
JP7125400B2 (ja) 2016-12-19 2022-08-24 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト 標的化４－１ｂｂ（ｃｄ１３７）アゴニストとの併用療法
CA3047070A1 (en) 2017-01-03 2018-07-12 F.Hoffmann-La Roche Ag Bispecific antigen binding molecules comprising anti-4-1bb clone 20h4.9
CN107056952A (zh) * 2017-05-10 2017-08-18 常州市第人民医院 Cea.car‑t及其制备与应用
CN107058234B (zh) * 2017-05-12 2019-09-13 常州市第一人民医院 Car.il-33-t及其制备与应用
JP7801095B2 (ja) 2017-08-01 2026-01-16 エイビー セラピューティクス インコーポレイテッド 二重特異性抗体およびその使用
EP3704155A2 (en) 2017-11-01 2020-09-09 F. Hoffmann-La Roche AG Combination therapy with targeted ox40 agonists
EP3502140A1 (en) 2017-12-21 2019-06-26 F. Hoffmann-La Roche AG Combination therapy of tumor targeted icos agonists with t-cell bispecific molecules
CN112566938B (zh) 2018-06-03 2025-04-01 拉姆卡普生物测试有限公司 针对ceacam5和cd47的双特异性抗体
TW202035447A (zh) 2018-07-04 2020-10-01 瑞士商赫孚孟拉羅股份公司 新穎雙特異性促效性4-1bb抗原結合分子
CR20210326A (es) 2018-12-21 2021-09-10 Hoffmann La Roche Moléculas agonistas de unión al antígeno cd28 que actúan sobre el tumor
CN113660956B (zh) 2019-01-28 2024-10-29 Ab诊疗公司 双特异性抗体及其用途
EP3693023A1 (en) 2019-02-11 2020-08-12 Sanofi Use of anti-ceacam5 immunoconjugates for treating lung cancer
KR20210124260A (ko) 2019-02-07 2021-10-14 사노피 폐암을 치료하기 위한 항-ceacam5 면역접합체의 용도
JP7137696B2 (ja) 2019-05-14 2022-09-14 プロヴェンション・バイオ・インコーポレイテッド １型糖尿病を予防するための方法および組成物
JP2022537158A (ja) 2019-06-13 2022-08-24 ボルト バイオセラピューティクス、インコーポレーテッド アミノベンズアゼピン化合物、イムノコンジュゲート、及びそれらの使用
EP3990492A1 (en) * 2019-06-27 2022-05-04 F. Hoffmann-La Roche AG Novel icos antibodies and tumor-targeted antigen binding molecules comprising them
WO2021041300A2 (en) * 2019-08-23 2021-03-04 Ab Therapeutics, Inc. Bispecific antibodies and uses thereof
US20220313835A1 (en) 2019-09-03 2022-10-06 Bolt Biotherapeutics, Inc. Aminoquinoline compounds, immunoconjugates, and uses thereof
AU2020350205A1 (en) 2019-09-18 2022-05-12 Lamkap Bio Alpha AG Bispecific antibodies against CEACAM5 and CD3
EP4038053A1 (en) 2019-09-30 2022-08-10 Bolt Biotherapeutics, Inc. Amide-linked, aminobenzazepine immunoconjugates, and uses thereof
EP4048315B1 (en) 2019-10-25 2025-03-12 Bolt Biotherapeutics, Inc. Thienoazepine immunoconjugates, and uses thereof
WO2021098822A1 (zh) * 2019-11-21 2021-05-27 江苏恒瑞医药股份有限公司 一种双特异性抗体
EP3831849A1 (en) 2019-12-02 2021-06-09 LamKap Bio beta AG Bispecific antibodies against ceacam5 and cd47
AR121706A1 (es) 2020-04-01 2022-06-29 Hoffmann La Roche Moléculas de unión a antígeno biespecíficas dirigidas a ox40 y fap
CA3176626A1 (en) 2020-05-08 2021-11-11 David Dornan Elastase-substrate, peptide linker immunoconjugates, and uses thereof
KR20230092863A (ko) 2020-06-11 2023-06-26 프로벤션 바이오, 인코포레이티드 제1형 당뇨병을 예방하기 위한 방법 및 조성물
MX2023001679A (es) 2020-08-13 2023-02-22 Bolt Biotherapeutics Inc Inmunoconjugados de pirazolazepina y usos de estos.
JP7849358B2 (ja) 2020-11-10 2026-04-21 サノフイ Ｃｅａｃａｍ５抗体－薬物コンジュゲート製剤
WO2022125891A2 (en) 2020-12-11 2022-06-16 Bolt Biotherapeutics, Inc. Anti-cea immunoconjugates, and uses thereof
US20220195066A1 (en) 2020-12-11 2022-06-23 Bolt Biotherapeutics, Inc. Anti-cea immunoconjugates, and uses thereof
KR20230121772A (ko) 2020-12-18 2023-08-21 람카프 바이오 베타 엘티디. Ceacam5 및 cd47에 대한 이중특이적 항체
CN117940168A (zh) 2021-03-26 2024-04-26 博尔特生物治疗药物有限公司 2-氨基-4-甲酰胺-苯并氮杂䓬免疫缀合物及其用途
CN117769439A (zh) 2021-03-26 2024-03-26 博尔特生物治疗药物有限公司 2-氨基-4-甲酰胺-苯并氮杂卓免疫缀合物及其用途
MX2023013851A (es) 2021-05-24 2023-12-08 Provention Bio Inc Metodos para el tratamiento de diabetes tipo 1.
AR126009A1 (es) 2021-06-02 2023-08-30 Hoffmann La Roche Moléculas agonistas de unión al antígeno cd28 que se dirigen a epcam
MX2024011519A (es) 2022-03-23 2024-09-24 Synaffix Bv Conjugados de anticuerpos para el direccionamiento contra tumores que expresan el antigeno carcinoembrionario.
CN119998319A (zh) 2022-06-16 2025-05-13 拉姆卡普生物测试有限公司 针对ceacam5和cd47的双特异性抗体与针对ceacam5和cd3的双特异性抗体的组合治疗
US20250043001A1 (en) 2023-03-14 2025-02-06 Xencor, Inc. Anti-cd28 compositions
WO2024261013A1 (en) 2023-06-21 2024-12-26 F. Hoffmann-La Roche Ag Combination therapy with fap-targeted lymphotoxin beta receptor agonists
CN121248779A (zh) * 2024-06-25 2026-01-02 冕屹立生物技术(上海)有限公司 靶向人cd3分子的抗体及其应用

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4394448A (en) 1978-02-24 1983-07-19 Szoka Jr Francis C Method of inserting DNA into living cells
JPH02500329A (ja) 1987-05-21 1990-02-08 クリエイテイブ・バイオマリキユールズ・インコーポレーテツド ターゲット化多機能蛋白質
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
GB9014932D0 (en) * 1990-07-05 1990-08-22 Celltech Ltd Recombinant dna product and method
DK0561907T3 (da) 1990-12-05 1999-05-31 Novo Nordisk As Proteiner med ændrede epitoper og fremgangsmåder til fremstilling deraf
EP0590058B1 (en) 1991-06-14 2003-11-26 Genentech, Inc. HUMANIZED Heregulin ANTIBODy
JP3626187B2 (ja) 1993-06-07 2005-03-02 バイカル インコーポレイテッド 遺伝子治療に適するプラスミド
CA2225460A1 (en) 1995-06-23 1997-01-09 Winston Campbell Patterson Transcriptional regulation of genes encoding vascular endothelial growth factor receptors
EP0983303B1 (en) 1997-05-21 2006-03-08 Biovation Limited Method for the production of non-immunogenic proteins
CA2326389C (en) 1998-04-21 2007-01-23 Micromet Gesellschaft Fur Biomedizinische Forschung Mbh Novel cd19xcd3 specific polypeptides and uses thereof
AU776910B2 (en) 1998-12-08 2004-09-23 Merck Patent Gesellschaft Mit Beschrankter Haftung Modifying protein immunogenicity
PL362324A1 (en) 2001-02-19 2004-10-18 Merck Patent Gmbh Artificial fusion proteins with reduced immunogenicity
US6992174B2 (en) 2001-03-30 2006-01-31 Emd Lexigen Research Center Corp. Reducing the immunogenicity of fusion proteins
US7820166B2 (en) * 2002-10-11 2010-10-26 Micromet Ag Potent T cell modulating molecules
US8076459B2 (en) 2003-10-16 2011-12-13 Micromet Ag Multispecfic deimmunized CD3-binders
US7235641B2 (en) * 2003-12-22 2007-06-26 Micromet Ag Bispecific antibodies
ITRM20030601A1 (it) * 2003-12-24 2005-06-25 Lay Line Genomics Spa Metodo per l'umanizzazione di anticorpi e anticorpi umanizzati con esso ottenuti.
WO2007071422A2 (en) * 2005-12-21 2007-06-28 Micromet Ag Pharmaceutical antibody compositions with resistance to soluble cea
NZ569204A (en) 2005-12-21 2012-03-30 Micromet Ag Pharmaceutical compositions with resistance to soluble CEA - comprising antibodies that bind to CD3 and CEA

Also Published As

Publication number Publication date
DK1976880T3 (en) 2016-09-26
US20130273050A1 (en) 2013-10-17
ZA200805400B (en) 2009-09-30
CN101370827A (zh) 2009-02-18
PL1976880T3 (pl) 2017-01-31
IL192277A (en) 2016-08-31
US20090226432A1 (en) 2009-09-10
US8394926B2 (en) 2013-03-12
KR101287777B1 (ko) 2013-07-23
EP1976880A1 (en) 2008-10-08
ME02581B (me) 2017-06-20
HUE031151T2 (en) 2017-06-28
US20170137538A1 (en) 2017-05-18
RU2426743C2 (ru) 2011-08-20
RS55181B1 (sr) 2017-01-31
AU2006328886B2 (en) 2011-04-14
CA2633766A1 (en) 2007-06-28
HK1115890A1 (zh) 2008-12-12
EP2527370A1 (en) 2012-11-28
PT1976880T (pt) 2016-09-28
KR20080079330A (ko) 2008-08-29
RU2010148652A (ru) 2012-06-10
US9982063B2 (en) 2018-05-29
JP2013056885A (ja) 2013-03-28
CN101370827B (zh) 2015-10-14
AU2006328886A1 (en) 2007-06-28
IL192277A0 (en) 2008-12-29
CA2633766C (en) 2016-06-28
EP1976880B1 (en) 2016-07-06
BRPI0620632A2 (pt) 2011-12-20
AU2006328886C1 (en) 2011-11-17
RU2573893C2 (ru) 2016-01-27
ES2595091T3 (es) 2016-12-27
HRP20161216T1 (hr) 2016-11-18
JP2009520734A (ja) 2009-05-28
LT1976880T (lt) 2016-10-10
JP5399712B2 (ja) 2014-01-29
CY1118053T1 (el) 2017-06-28
US9695250B2 (en) 2017-07-04
WO2007071426A1 (en) 2007-06-28
NZ569204A (en) 2012-03-30
RU2008129787A (ru) 2010-01-27

Similar Documents

Publication Publication Date Title
DK1976880T3 (en) Pharmaceutical compositions with resistance to soluble cea
US8901278B2 (en) Pharmaceutical antibody compositions with resistance to soluble CEA
KR101671039B1 (ko) 항 ｃｘｃｒ4 항체 및 그들의 암의 치료를 위한 용도
JP2022516505A (ja) 癌および他の疾患の治療のための、クローディン１８．２に特異的な結合分子、その組成物および方法
KR20210031913A (ko) 항-인간 pd-l1 항체 및 그것의 용도
AU2011204778B2 (en) Pharmaceutical compositions with resistance to soluble CEA
HK1115890B (en) Pharmaceutical compositions with resistance to soluble cea
HK1178548A (en) Compounds having resistance to soluble cea
JP2025516434A (ja) 抗ｃｄ７３抗体およびその使用
NZ569144A (en) Pharmaceutical antibody compositions with resistance to soluble CEA - comprising IgG1antibodies that bind to CEA